Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POU2F2 | P09086 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | SLC22A2 | O15244 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186003 | 0.87 | POU2F2 (0.45) | POU2F2SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL2185785 | 0.84 | POU2F2 (0.47) | POU2F2 | |
| SCHEMBL3528387 | 0.84 | POU2F2 (0.47) | POU2F2 | |
| SCHEMBL2185698 | 0.83 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL3521604 | 0.80 | POU2F2 (0.43) | POU2F2 | |
| SCHEMBL81275 | 0.78 | POU2F2 (0.50) | POU2F2POLBRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL22469550 | 0.78 | POU2F2 (0.50) | POU2F2RXFP1SLC22A2 | |
| SCHEMBL22482391 | 0.78 | POU2F2 (0.50) | POU2F2RXFP1SLC22A2 | |
| SCHEMBL2186585 | 0.78 | POU2F2 (0.45) | POU2F2SLC22A2 | |
| SCHEMBL82612 | 0.76 | SLC22A2 (0.45) | SLC22A2CYP3A4TMEM97ABCG2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852434-B1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7858788-B2 | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852434-A1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | Shionogi Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | NR4A1, HAT1, NR4A2 | POU2F2 294/4885POLB 619/4885RAB9A 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.